These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 8587069

  • 1. Use of second line drugs for the treatment of rheumatoid arthritis in Edmonton, Alberta. Patterns of prescription and longterm effectiveness.
    Suarez-Almazor ME, Soskolne CL, Saunders LD, Russell AS.
    J Rheumatol; 1995 May; 22(5):836-43. PubMed ID: 8587069
    [Abstract] [Full Text] [Related]

  • 2. Variations and trends in the prescription of initial second line therapy for patients with rheumatoid arthritis.
    Galindo-Rodriguez G, Avina-Zubieta JA, Fitzgerald A, LeClerq SA, Russell AS, Suarez-Almazor ME.
    J Rheumatol; 1997 Apr; 24(4):633-8. PubMed ID: 9101493
    [Abstract] [Full Text] [Related]

  • 3. Practice variation in the treatment of rheumatoid arthritis among German rheumatologists.
    Zink A, Listing J, Ziemer S, Zeidler H, German Collaborative Arthritis Centres.
    J Rheumatol; 2001 Oct; 28(10):2201-8. PubMed ID: 11669156
    [Abstract] [Full Text] [Related]

  • 4. Disappointing longterm results with disease modifying antirheumatic drugs. A practice based study.
    Galindo-Rodriguez G, Aviña-Zubieta JA, Russell AS, Suarez-Almazor ME.
    J Rheumatol; 1999 Nov; 26(11):2337-43. PubMed ID: 10555887
    [Abstract] [Full Text] [Related]

  • 5. Longterm methotrexate use in rheumatoid arthritis: 12 year followup of 460 patients treated in community practice.
    Wluka A, Buchbinder R, Mylvaganam A, Hall S, Harkness A, Lewis D, Littlejohn GO, Miller MH, Ryan PF.
    J Rheumatol; 2000 Aug; 27(8):1864-71. PubMed ID: 10955325
    [Abstract] [Full Text] [Related]

  • 6. Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: a survey of practicing Canadian rheumatologists.
    Pope JE, Hong P, Koehler BE.
    J Rheumatol; 2002 Feb; 29(2):255-60. PubMed ID: 11838842
    [Abstract] [Full Text] [Related]

  • 7. Differences in the use of second-line agents and prednisone for treatment of rheumatoid arthritis by rheumatologists and non-rheumatologists.
    Criswell LA, Such CL, Yelin EH.
    J Rheumatol; 1997 Dec; 24(12):2283-90. PubMed ID: 9415629
    [Abstract] [Full Text] [Related]

  • 8. Longterm observational study of methotrexate use in a Dutch cohort of 1022 patients with rheumatoid arthritis.
    Hoekstra M, van de Laar MA, Bernelot Moens HJ, Kruijsen MW, Haagsma CJ.
    J Rheumatol; 2003 Nov; 30(11):2325-9. PubMed ID: 14677172
    [Abstract] [Full Text] [Related]

  • 9. How Canadian and US rheumatologists treat moderate or aggressive rheumatoid arthritis: a survey.
    Maetzel A, Bombardier C, Strand V, Tugwell P, Wells G.
    J Rheumatol; 1998 Dec; 25(12):2331-8. PubMed ID: 9858426
    [Abstract] [Full Text] [Related]

  • 10. Initial disease modifying antirheumatic drugs and prednisolone prescriptions for patients with rheumatoid arthritis: a 15-year study.
    Osiri M, Akkasilpa S, Deesomchok U.
    J Med Assoc Thai; 2000 Mar; 83(3):217-24. PubMed ID: 10808674
    [Abstract] [Full Text] [Related]

  • 11. Prescription rheumatology practices among Mexican specialists.
    Goycochea-Robles MV, Arce-Salinas CA, Guzmán-Vázquez S, Cardiel-Ríos MH.
    Arch Med Res; 2007 Apr; 38(3):354-9. PubMed ID: 17350489
    [Abstract] [Full Text] [Related]

  • 12. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
    Rau R, Schleusser B, Herborn G, Karger T.
    J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088
    [Abstract] [Full Text] [Related]

  • 13. Disease modifying antirheumatic drugs in early rheumatoid arthritis: a longterm observational study.
    Papadopoulos NG, Alamanos Y, Papadopoulos IA, Tsifetaki N, Voulgari PV, Drosos AA.
    J Rheumatol; 2002 Feb; 29(2):261-6. PubMed ID: 11838843
    [Abstract] [Full Text] [Related]

  • 14. Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis.
    Gonzalez-Alvaro I, Carmona L, Balsa A, Sanmarti R, Belmonte MA, Tena X, EMECAR Study Group.
    J Rheumatol; 2003 Apr; 30(4):697-704. PubMed ID: 12672186
    [Abstract] [Full Text] [Related]

  • 15. Most rheumatologists are conservative in active rheumatoid arthritis despite methotrexate therapy: results of the PRISME survey.
    Saraux A, Devauchelle-Pensec V, Engerran L, Flipo RM.
    J Rheumatol; 2006 Jul; 33(7):1258-65. PubMed ID: 16783865
    [Abstract] [Full Text] [Related]

  • 16. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
    van Roon EN, van den Bemt PM, Jansen TL, Houtman NM, van de Laar MA, Brouwers JR.
    Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132
    [Abstract] [Full Text] [Related]

  • 17. How do French rheumatologists treat early rheumatoid arthritis?
    de Asit N, Le Loët X, Czernichow P, Bertho JM, Delcambre B, Tonnel F, Loyau G, Dapogny C, Trèves R, Valat JP, Tauveron P, Sebert JL, Boumier P.
    Rev Rhum Engl Ed; 1996 Mar; 63(3):188-95. PubMed ID: 8731236
    [Abstract] [Full Text] [Related]

  • 18. Trends in disease modifying antirheumatic drug prescription in early rheumatoid arthritis are influenced more by hospital setting than patient or disease characteristics.
    Carli C, Ehlin AG, Klareskog L, Lindblad S, Montgomery SM.
    Ann Rheum Dis; 2006 Aug; 65(8):1102-5. PubMed ID: 16322085
    [Abstract] [Full Text] [Related]

  • 19. Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences.
    Fautrel B, Guillemin F, Meyer O, de Bandt M, Berthelot JM, Flipo RM, Lioté F, Maillefert JF, Wendling D, Saraux A, Combe B, Le Loët X, Stratégies Thérapeutiques dans La Polyarthrite RhumatoIde Working Group, Club Rhumatismes et Inflammation, French Society of Rheumatology.
    Arthritis Rheum; 2009 Apr 15; 61(4):425-34. PubMed ID: 19333993
    [Abstract] [Full Text] [Related]

  • 20. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients.
    Sokka T, Pincus T.
    J Rheumatol; 2002 Dec 15; 29(12):2521-4. PubMed ID: 12465145
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.